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CASE REPORT
Mammary gland tumors in a male 
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Abstract 
Background: Mammary gland tumors are the most common tumors in sexually intact female dogs; however, they 
are rare in male dogs. This study was conducted to investigate the relationship between sexual hormones and mam‑
mary gland tumors in a male dog.
Case presentation: A 13‑year‑old, intact male Cocker Spaniel presented to the Veterinary Teaching Hospital of 
Kangwon National University, Republic of Korea, with an acute right ruptured caudal abdominal mass. Physical 
examination revealed a 14 × 14 cm ruptured mass in the right caudal abdomen, as well as a 1.5 × 1.5 cm mass in the 
first right mammary gland. The estrogen and progesterone concentrations in serum were within normal levels. Total 
mastectomy was done on the right side mammary glands. Following surgery, the site was fully recovered; however, 
a mass that had grown to 2 × 2 cm was found in the left fifth mammary gland and a testis tumor was also found 
over the period of 4 months. Mastectomy was performed on the left caudal mammary gland and castration was also 
performed. After the final surgery, the dog fully recovered. Histopathological examination of all three masses revealed 
high grade mammary adenocarcinoma in the mammary gland and the testis was diagnosed as Leydig cell adenoma. 
Immunohistochemical analysis revealed that the estrogen and progesterone receptors were expressed on limited 
cells in mammary and testis tumors.
Conclusion: The results of this study suggest that mammary tumors and testes tumors can occur in male dogs with‑
out relationship to female sexual hormone.
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Background
Mammary gland tumors are the most common tumors 
in sexually intact female dogs [1]. Most mammary 
gland tumors in female dogs are of epithelial origin, and 
approximately 50% are malignant [2, 3]. The main sus-
pected risk factors for mammary tumors are age, hor-
mone exposure, and breed. Mammary tumors affect 
middle-age and older dogs, and tend to be more common 
in smaller breeds [1]. Previous studies suggested that 
early spayed female dogs have reduced risk of mammary 
gland tumor development, and that those spayed prior to 
the first estrus have only a 0.5% risk of mammary gland 
tumors as compared to intact females. However, there 
are no significant benefits of ovariohysterectomy after 
4  years of age [4]. These results showed that blocking 
heat cycles in dogs can prevent mammary gland tumors, 
which suggests that ovarian hormones are important fac-
tors influencing the formation mammary gland tumors. 
Indeed, it has been reported that exposure to exogenous 
or pharmacologic hormones such as progestin and estro-
gen increase the risk of developing mammary tumors 
in dogs [5]. However, not all mammary tumors have 
reactivity with hormonal receptor antibody, with only 
approximately 50–77% of epithelial mammary gland 
tumors expressing hormonal receptors [6]. These find-
ings showed that exposure to factors other than sexual 
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hormones can involve mammary gland tumors in some 
cases.
Mammary gland tumors are rare in male dogs, as indi-
cated by their being 62 times less likely to develop mam-
mary gland tumors than female dogs [7]. Breast cancer 
in men is also uncommon in humans, accounting for 
only 1% of all diagnosed breast cancers [8]. The possible 
risk factors of breast cancers in men include increasing 
age, testicular injury, obesity, gynecomastia, Klinefelter’s 
syndrome and a family history of breast cancer [9, 10]. 
Accordingly, sexual hormones are a suspected factor of 
breast cancer in men, and various studies of the relation-
ship between breast cancer in men and sexual hormones 
have been conducted [11, 12].
The present study was conducted to investigate the 
relationship between sexual hormone and mammary 
gland tumors in a male dog, which is especially rare in 
veterinary medicine.
Case presentation
A 13-year-old, intact male Cocker Spaniel presented to 
the Veterinary Teaching Hospital of Kangwon National 
University, Republic of Korea with an acute right rup-
tured caudal abdominal mass. Three months before com-
ing to Kangwon National University, a mass was found 
and developed for three months. Physical examination 
revealed a 14 × 14 cm ruptured mass in the right caudal 
abdomen found, as well as a 1.5 × 1.5 cm mass in the first 
right mammary gland. Hematological analysis revealed 
moderate neutrophilia. Abnormality in the serum bio-
chemistry included elevated gamma-glutamyl trans-
ferase and alkaline phosphatase. The estrogen (42.5  pg/
ml: reference range is 31.5–65.4 pg/ml) and progesterone 
(<0.2  ng/ml:  <1.0  ng/ml in the anestrus phase) levels in 
the serum were within the normal ranges. Assessment 
of estrogen was performed by chemiluminescent immu-
noassay in IDEXX Estradiol by RIA, while progesterone 
was assessed using an IMMULITE kit (IDEXX Reference 
Laboratories, Westbrook, ME, USA). Nothing remark-
able were observed upon thoracic radiography; however, 
two superficial masses were identified during abdominal 
radiography. Abdominal ultrasonography demonstrated 
that there were no abnormal changes in the regional 
lymph nodes. Total mastectomy of the right side mam-
mary glands was conducted. After surgery, the surgery 
site was fully recovered; however, a mass was found in 
the left fifth mammary gland that had grown to 2 × 2 cm 
over 119  days, as well as a testis tumor. The mass was 
removed and castration was performed. The dog fully 
recovered and there was no recurrence on the resident 
left mammary region as of 750 days after the last surgery.
Microscopic examination of these three mammary 
gland masses revealed a moderate to high grade invasive 
mammary carcinoma in a benign mixed tumor [3, 13, 
14]. The masses were uncapsulated and exhibited stromal 
invasion in some locations (Fig.  1a–c). Tumor cells were 
pleomorphic, ranging from columnar to cuboidal to more 
polygonal, forming cords, variably-sized nests or glands 
(Fig. 1e). These cells had scant to moderate cytoplasm with 
moderate anisokaryosis and coarse to hyperchromatic 
nuclei. Variable amounts of chondroid and osseous matri-
ces and diffused mast cells were observed within the sup-
porting stromal connective tissue of the mass (Fig. 1d–f).
The microscopic features of the masses in the tes-
tis were revealed as Leydig cells adenoma and showed 
characteristic trabecular structures separated by thin 
fibrovascular structures. These neoplastic cells had an 
epithelial or columnar amphophilic cytoplasm with 
monomorphic round nuclei. Degenerating seminiferous 
tubules were also observed in the tumor region. However, 
mitotic features were not seen in tumor regions (Fig. 2a, 
b). No significant morphological changes in seminiferous 
tubules or interstitial tissues were observed in non-tumor 
regions (Fig. 2c).
For immunohistochemical analysis, estrogen receptor 
alpha (ERα, 1:200, anti-estrogen receptor alpha antibody 
[E115], Abcam, Korea) and progesterone receptor (PR, 
1:200, anti-progesterone receptor antibody [PR-AT 4.14], 
Abcam, Korea) were used in three mammary tumors and 
testis.
In the mammary tumor, ERα-immunoreactivity was 
detected in the tumor tissues; however, only a few epi-
thelial cells adjacent to the duct and invasive region 
were immunopositive for ERα (Fig.  1g–i). In the stro-
mal tissue of the mass, some darkly stained large ERα-
immunoreactive cells were observed (Fig.  1g–i). These 
cells were identified as mast cells based on their morphol-
ogy and the results of toluidine blue staining (Fig. 1m–o). 
PR- immunoreactivity was also observed in mammary 
tumor tissues with similar patterns as for ERα (Fig. 1j–l).
ERα-immunoreactivity was detected in the spermato-
gonia, spermatocytes, spermatids and Sertoli cells of 
the seminiferous tubule in both tumor and non-tumor 
regions. Some ERα-immunoreactive-Leydig cells were 
also observed in the non-tumor regions. However, ERα-
immunoreactive Leydig cells were not observed in the 
tumor region (Fig.  2d, e). PR-immunoreactivity was 
also observed in the seminiferous tubules of tumor and 
non-tumor regions (Fig. 2g–i). Spermatocytes and some 
Leydig cells were darkly stained with PR, and round sper-
matids were weakly stained with PR in the non-tumor 
region (Fig.  2h, i). Scant PR-immunoreactive spermato-
gonia were also observed (Fig.  2i). Most Leydig cells 
in the tumor region were not positive for PR antibody, 
except for a few PR-immunoreactive Leydig cells in the 
boundary of tumor and non-tumor regions (Fig. 2h).
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Fig. 1 Low and high magnification photos of various regions of the mammary tumor, HE. Desmoplasia (a, d), chondroid components (b, e), 
osseous tissues adjacent duts (c) and diffused mast cells (arrowheads) in stroma (f). Immunohistochemistry of ERα (g–i) and PR (j–l) in the tumor. 
Toluidine blue (TB) staining for mast cells (n–o). Arrows indicate epithelial cells. Scale bars 250 µm (a, b, g, j, m), 100 µm (c–f, h, k, n) and 50 µm (i, l, p)
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Conclusions
The influence of sexual hormones in tumorigenesis has 
been investigated in various species, including dogs [1]. 
Sexual hormones, including estrogen and progesterone, 
are essential for physiological mammary growth and 
development, not only during pregnancy, but through-
out the reproductive cycle [15]. The effects of these hor-
mones are mediated via binding to their own receptors 
[16]. It can be assumed that changes in both ER and PR in 
any tissue indicate that there are estrogen and progester-
one hormonal effects on related tissues [17]. Accordingly, 
many studies have investigated the expression of ER and 
PR in mammary gland tumors [16, 17], and hormonal 
therapies using hormone receptor antagonists have been 
attempted in mammary gland tumors based on these 
studies. Surgical excision is the first line treatment of 
veterinary mammary tumors. However approximately 
one-third of these tumors will recur and metastasize [18]. 
Therefore to prevent recurrence and metastasis, other 
trials, including chemotherapy, should be considered. 
One study showed that PR antagonist had PR expression 
related inhibiting effects on proliferation of canine mam-
mary carcinoma cells [19].
Contrary to these findings, some studies have also 
shown that estrogen levels in inflammatory mammary 
carcinoma in female dogs were lower than when com-
pared to animals with other carcinoma subtypes [20]. 
These results conflict with the opinion that sexual hor-
mones influence tumorigenesis in mammary gland 
tumors. Therefore it is doubtful that early spaying in dogs 
can decrease the risk of mammary tumors. Actually, the 
strength in evidence for a preventive effect of neutering 
Fig. 2 Leydig cells adenoma in the testis (a), HE. High magnification photos of tumor region (asterisk, b) and non‑tumor region (c). Immunohisto‑
chemistry of ERα (d, e) and PR (g–i) in the tumor and non‑tumor regions of the testis. Arrowheads (spermatogonium), arrows (Leydig cells), open 
arrowheads (spermatocytes), open arrows (spermatids). Scale bars 400 µm (a), 200 µm (d, g), 100 µm (b, c, e, f, h, i)
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has been questioned [21]. Some groups have shown that 
ERα is down-regulated in high grade breast cancer. The 
expression of ERα and PR is related to the clinical and 
biological specificity of the breast cancer [22, 23]. Based 
on these results, we can assume that the grade of the 
mammary gland tumors is an important factor in expres-
sion of ERα and PR in mammary gland tumors.
Breast cancer in men is rare, and most instances have 
been diagnosed as malignancies [9]. Breast cancer in 
men has also been considered to be related to estrogen 
and progesterone, with approximately 65–80 and 90% 
of breast cancer cases in men being ER and PR positive, 
respectively [24, 25]. However, under similar conditions, 
we can assume that 20–35% of breast cancer in men is 
not associated with ER and that 10% of breast cancer in 
men is not associated with PR.
Few studies have investigated mammary gland tumors 
in male dogs, and only one has reported their diagnosis 
in male dogs with a subsequent assessment of these dogs 
[7]. In this study, seven of eight dogs had benign tumors, 
while only one dog suffered from malignant tumor. There 
were also no recurrences in the seven dogs with benign 
tumors, but one dog with malignant tumor developed 
local recurrence. Identification of the new tumor was 
noted approximately 115 days after the original diagnosis 
in this dog. ER expression was intense and occurred in 
neoplastic cells, while PR expression was less intense in 
neoplastic cells in most dogs. Unfortunately in this study, 
they could not confirm the relationship between castra-
tion and mammary tumors in male dogs [7].
In the present study, a male dog presented with mam-
mary tumors. Following the first mastectomy, high grade 
mammary adenocarcinoma was diagnosed. However, a 
new mammary gland tumor occurred after 119  days as 
well as a testis tumor. Upon histopathological examina-
tion, the testicular tumor was diagnosed as Leydig cell 
adenoma. There had been no recurrence as of 750  days 
after surgical removal. However, these findings are not 
sufficient to explain the relationship between castration 
and mammary tumors in this case or in male dogs. In 
this study, there was no clear expression of ER and PR in 
neoplastic cells of mammary tumors and testis tumors. 
These results conflict with previous reports that estrogen 
is highly produced in the Leydig cell adenoma in some 
cases [26]. We can only assume that the high grade ade-
nocarcinoma in mammary glands affected the expression 
of ER and PR in neoplastic cells.
This study confirmed the presence of malignant mam-
mary tumors and Leydig cell adenoma of the testis in one 
male dog. The results suggests that mammary tumors 
and testes tumors in male dogs can occur without rela-
tionship to female sexual hormones.
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